What is Wedbush's Forecast for Scholar Rock Q3 Earnings?

Key Points

• Wedbush Brokers have revised their Q3 2025 earnings estimates for Scholar Rock, now predicting a loss of ($0.70) per share, compared to a previous estimate of ($0.64).
• Scholar Rock's recent quarterly earnings report showed a loss of ($0.98) per share, missing the consensus estimate by ($0.32).
• Despite recent downgrades, Scholar Rock has received several buy and strong-buy ratings from analysts, maintaining a consensus rating of "Buy" with an average target price of $45.14.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - Research analysts at Wedbush dropped their Q3 2025 earnings per share estimates for shares of Scholar Rock in a research note issued to investors on Wednesday, August 6th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.70) per share for the quarter, down from their prior estimate of ($0.64). Wedbush currently has a "Outperform" rating and a $50.00 target price on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Scholar Rock's FY2025 earnings at ($2.98) EPS, Q1 2026 earnings at ($0.60) EPS, Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($0.36) EPS and FY2028 earnings at $0.89 EPS.

Other equities analysts have also issued reports about the stock. Raymond James Financial set a $53.00 price target on shares of Scholar Rock and gave the stock a "strong-buy" rating in a research report on Wednesday, July 30th. Lifesci Capital raised shares of Scholar Rock to a "strong-buy" rating in a research note on Tuesday, June 3rd. Cantor Fitzgerald initiated coverage on shares of Scholar Rock in a research note on Thursday, July 17th. They set an "overweight" rating on the stock. Finally, BMO Capital Markets decreased their price target on shares of Scholar Rock from $57.00 to $45.00 and set an "outperform" rating on the stock in a research note on Thursday, August 7th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $45.14.

Scholar Rock Stock Performance

Shares of SRRK stock traded up $0.74 during trading hours on Monday, reaching $32.20. The company had a trading volume of 1,224,470 shares, compared to its average volume of 1,225,593. The business has a fifty day moving average price of $35.78 and a 200-day moving average price of $34.28. Scholar Rock has a one year low of $6.76 and a one year high of $46.98. The firm has a market cap of $3.10 billion, a PE ratio of -11.07 and a beta of 0.48. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.33 and a current ratio of 6.33.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.32). During the same quarter in the prior year, the firm earned ($0.60) EPS.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors have recently made changes to their positions in the company. CWM LLC boosted its position in Scholar Rock by 152.8% in the 1st quarter. CWM LLC now owns 996 shares of the company's stock valued at $32,000 after buying an additional 602 shares during the period. Federated Hermes Inc. purchased a new position in shares of Scholar Rock in the 1st quarter valued at $71,000. GF Fund Management CO. LTD. grew its position in shares of Scholar Rock by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company's stock valued at $77,000 after buying an additional 430 shares during the last quarter. Strs Ohio purchased a new position in shares of Scholar Rock in the 1st quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Scholar Rock by 15.8% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company's stock valued at $130,000 after buying an additional 500 shares during the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Scholar Rock

In other news, Director Kristina Burow sold 5,400 shares of the company's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $29.72, for a total transaction of $160,488.00. Following the transaction, the director owned 21,071 shares in the company, valued at $626,230.12. This represents a 20.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey S. Flier sold 20,316 shares of the company's stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $32.24, for a total value of $654,987.84. Following the completion of the transaction, the director directly owned 24,070 shares in the company, valued at approximately $776,016.80. The trade was a 45.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 93,654 shares of company stock worth $3,101,811. 13.30% of the stock is currently owned by company insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.